[go: up one dir, main page]

WO2012035508A3 - Method for separating target molecules or particles from fibrinogen-containing samples including blood components - Google Patents

Method for separating target molecules or particles from fibrinogen-containing samples including blood components Download PDF

Info

Publication number
WO2012035508A3
WO2012035508A3 PCT/IB2011/054035 IB2011054035W WO2012035508A3 WO 2012035508 A3 WO2012035508 A3 WO 2012035508A3 IB 2011054035 W IB2011054035 W IB 2011054035W WO 2012035508 A3 WO2012035508 A3 WO 2012035508A3
Authority
WO
WIPO (PCT)
Prior art keywords
particles
fibrinogen
target molecules
blood components
including blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/054035
Other languages
French (fr)
Other versions
WO2012035508A2 (en
WO2012035508A4 (en
Inventor
Amar Rida
Nicolas Mermod
Patrice Francois
Vladimir Lazarevic
Jacques Schrenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spinomix SA
Original Assignee
Spinomix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL11788227T priority Critical patent/PL2616550T3/en
Priority to EP11788227.4A priority patent/EP2616550B1/en
Priority to DK11788227.4T priority patent/DK2616550T3/en
Priority to US13/822,209 priority patent/US9689881B2/en
Priority to CN201180044211.XA priority patent/CN103108959B/en
Priority to ES11788227T priority patent/ES2571127T3/en
Priority to AU2011303467A priority patent/AU2011303467C1/en
Priority to KR1020137009329A priority patent/KR101948944B1/en
Priority to CA2811493A priority patent/CA2811493C/en
Priority to EP16154770.8A priority patent/EP3067431B1/en
Priority to PL16154770T priority patent/PL3067431T3/en
Application filed by Spinomix SA filed Critical Spinomix SA
Priority to JP2013528815A priority patent/JP5999776B2/en
Publication of WO2012035508A2 publication Critical patent/WO2012035508A2/en
Publication of WO2012035508A3 publication Critical patent/WO2012035508A3/en
Publication of WO2012035508A4 publication Critical patent/WO2012035508A4/en
Anticipated expiration legal-status Critical
Priority to AU2016266066A priority patent/AU2016266066B2/en
Priority to US15/601,677 priority patent/US20170336424A1/en
Priority to CY20191101074T priority patent/CY1122166T1/en
Priority to US17/160,814 priority patent/US20210148940A1/en
Priority to US18/231,880 priority patent/US20240280593A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/14—Streptococcus; Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

A method for separating target molecules or particles from a fibrinogen containing sample comprises: (a) trapping the said target molecules or particles in a fibrin network by converting at least partially the fibrinogen contained in the sample into fibrin; (b) retracting the said fibrin network to form a fibrin clot; (c) separating the said fibrin clot from the surrounding sample medium,
PCT/IB2011/054035 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components Ceased WO2012035508A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
PL16154770T PL3067431T3 (en) 2010-09-15 2011-09-15 Device including blood components for separating target molecules or particles from samples
DK11788227.4T DK2616550T3 (en) 2010-09-15 2011-09-15 Process for Separating Target Molecules or Particles from Fibrinogen-Containing Samples Including Blood Components
US13/822,209 US9689881B2 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
CN201180044211.XA CN103108959B (en) 2010-09-15 2011-09-15 Method for isolating target molecules or particles from fibrinogen-containing samples including blood components
ES11788227T ES2571127T3 (en) 2010-09-15 2011-09-15 Method for separation of target molecules or particles from samples containing fibrinogen, including blood components
AU2011303467A AU2011303467C1 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
JP2013528815A JP5999776B2 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from a fibrinogen-containing sample containing blood components
EP11788227.4A EP2616550B1 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
EP16154770.8A EP3067431B1 (en) 2010-09-15 2011-09-15 Device including blood components for separating target molecules or particles from samples
PL11788227T PL2616550T3 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
CA2811493A CA2811493C (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
KR1020137009329A KR101948944B1 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
AU2016266066A AU2016266066B2 (en) 2010-09-15 2016-12-02 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
US15/601,677 US20170336424A1 (en) 2010-09-15 2017-05-22 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
CY20191101074T CY1122166T1 (en) 2010-09-15 2019-10-11 DEVICE INCLUDING BLOOD COMPONENTS FOR SEPARATION OF TARGET MOLECULES OR PARTICLES FROM SAMPLES
US17/160,814 US20210148940A1 (en) 2010-09-15 2021-01-28 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
US18/231,880 US20240280593A1 (en) 2010-09-15 2023-08-09 Method for separating target molecules or particles from fibrinogen-containing samples including blood components

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH01478/10 2010-09-15
CH14782010 2010-09-15
CH20412010 2010-12-07
CH02041/10 2010-12-07
CH12072011 2011-07-20
CH01207/11 2011-07-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/822,209 A-371-Of-International US9689881B2 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components
US15/601,677 Continuation US20170336424A1 (en) 2010-09-15 2017-05-22 Method for separating target molecules or particles from fibrinogen-containing samples including blood components

Publications (3)

Publication Number Publication Date
WO2012035508A2 WO2012035508A2 (en) 2012-03-22
WO2012035508A3 true WO2012035508A3 (en) 2012-05-18
WO2012035508A4 WO2012035508A4 (en) 2012-07-19

Family

ID=45044632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/054035 Ceased WO2012035508A2 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components

Country Status (17)

Country Link
US (4) US9689881B2 (en)
EP (2) EP3067431B1 (en)
JP (1) JP5999776B2 (en)
KR (1) KR101948944B1 (en)
CN (2) CN107389932B (en)
AU (2) AU2011303467C1 (en)
CA (1) CA2811493C (en)
CY (1) CY1122166T1 (en)
DK (2) DK3067431T3 (en)
ES (2) ES2571127T3 (en)
HR (1) HRP20191785T1 (en)
HU (2) HUE045771T2 (en)
LT (1) LT3067431T (en)
PL (2) PL2616550T3 (en)
PT (1) PT3067431T (en)
SI (1) SI3067431T1 (en)
WO (1) WO2012035508A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3067431B1 (en) 2010-09-15 2019-07-24 Debiopharm International S.A. Device including blood components for separating target molecules or particles from samples
US9688959B2 (en) 2011-06-27 2017-06-27 Emory University Compositions, uses, and preparation of platelet lysates
EP2979093B1 (en) * 2013-03-29 2019-10-23 Siemens Healthcare Diagnostics Inc. Rare cell concentration
WO2015186049A1 (en) 2014-06-01 2015-12-10 Debiopharm International Sa Sample collection and processing device
CN108290166B (en) 2015-11-30 2021-07-20 Dh科技发展私人贸易有限公司 Electromagnetic assemblies for handling fluids
US10596236B2 (en) 2016-03-10 2020-03-24 Arthrex, Inc. Systems and methods for preparing a thrombin serum
US10960026B2 (en) 2016-03-10 2021-03-30 Arthrex, Inc. Systems and methods for preparing protein enhanced serums
BR112020024296A2 (en) 2018-08-27 2021-03-09 Regeneron Pharmaceuticals, Inc. METHODS FOR THE PRODUCTION OF A CONCENTRATED PROTEIN PURIFICATION INTERMEDIATE, FOR MONITORING AND CONTROL OF CRITICAL QUALITY ATTRIBUTES IN A PROTEIN PURIFICATION INTERMEDIATE AND TO MONITOR AND CONTROL THE EXCIPIENT LEVELS IN THE CULTURE AND CULTURE FLUID FLUID. PROTEIN, AND, PROTEIN PURIFICATION INTERMEDIATE
JP7298449B2 (en) * 2019-11-14 2023-06-27 株式会社島津製作所 Blood coagulation analyzer and cleaning method for dispensing nozzle

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068662A1 (en) * 1987-12-24 2003-04-10 Institut Pasteur Reagent for the detection of Staphylococcus aureus by agglutination
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
WO2007015782A1 (en) * 2005-07-29 2007-02-08 Ecole Polytechnique Federale De Lausanne Molecular variant fibrinogen fusion proteins
WO2010004004A1 (en) * 2008-07-09 2010-01-14 Profibrix Bv Recombinant fibrinogen

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1035260A (en) * 1974-08-12 1978-07-25 Baxter Travenol Laboratories Collection and processing tube
DE3803463A1 (en) * 1988-02-05 1989-08-17 Linhart Axel Rapid semiquantitative calcium assay
DE58902472D1 (en) * 1988-01-05 1992-11-26 Linhart Axel METHOD AND TEST KIT FOR SEMIQUANTITATIVE DETERMINATION OF THE CALCIUM CONTENT IN BLOOD.
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
EP0587398B1 (en) * 1992-09-09 1998-01-14 Tokuyama Corporation Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof
JP3292760B2 (en) * 1993-04-22 2002-06-17 テルモ株式会社 Blood collection tube and method for producing the same
US5670329A (en) * 1993-05-28 1997-09-23 Cardiovascular Diagnostics, Inc. Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field
CA2176810A1 (en) 1993-12-03 1995-06-08 Gordon L. Dorn Method for improving quantitative recovery of microorganisms from speci mens containing blood components
DE19602673A1 (en) * 1996-01-25 1997-08-07 Pereg Gmbh Synthetic test soiling
US6121232A (en) * 1997-01-31 2000-09-19 Omrix Biopharmaceuticals Sa Stabilized mixture comprising fibrinogen
JP2000262499A (en) * 2000-01-01 2000-09-26 Terumo Corp Blood collecting tube
US6686204B2 (en) * 2001-08-27 2004-02-03 Becton, Dickinson & Company Collection device
CN1606447A (en) * 2001-10-03 2005-04-13 克里斯托弗·J·伍尔弗顿 Storage-stable fibrinogen solutions
US8802386B2 (en) * 2002-05-01 2014-08-12 Synapse B.V. Diagnostic test for determining the concentration of transient proteolytic activity in composite biological media
DE50207801D1 (en) 2002-09-18 2006-09-21 Sirs Lab Gmbh Method for detecting prokaryotic DNA
PT2103694E (en) * 2003-08-15 2011-07-26 Univ South Florida Materials and methods for capture of pathogens and removal of aurintricarboxylic acid from a sample
US20050065454A1 (en) * 2003-09-22 2005-03-24 Becton, Dickinson And Company Non-evacuated blood collection tube
US7399609B2 (en) * 2003-12-30 2008-07-15 3M Innovative Properties Company Staphylococcus detection
US8419722B2 (en) * 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
DE102005009479A1 (en) 2005-03-02 2006-09-07 Molzym Gmbh & Co. Kg Use of nucleases for the degradation of nucleic acid in the presence of chaotropic agents and / or surfactants
WO2008137673A1 (en) * 2007-05-03 2008-11-13 Accumetrics, Inc. Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists
ES2531455T3 (en) 2007-08-02 2015-03-16 UNIVERSITé LAVAL Concentration and enrichment of microbial cells and microbial nucleic acids from body fluids
JP5029217B2 (en) * 2007-08-27 2012-09-19 東レ株式会社 Manufacturing method of sheet-like material
US9353160B2 (en) 2009-07-16 2016-05-31 Glaxosmithkline Biologicals S.A. Method of prophlactically treating infection using a recombinant fibrinogen binding protein clumping factor A (ClfA) or fragment thereof
EP3067431B1 (en) 2010-09-15 2019-07-24 Debiopharm International S.A. Device including blood components for separating target molecules or particles from samples

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068662A1 (en) * 1987-12-24 2003-04-10 Institut Pasteur Reagent for the detection of Staphylococcus aureus by agglutination
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
WO2007015782A1 (en) * 2005-07-29 2007-02-08 Ecole Polytechnique Federale De Lausanne Molecular variant fibrinogen fusion proteins
WO2010004004A1 (en) * 2008-07-09 2010-01-14 Profibrix Bv Recombinant fibrinogen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. GREENE, 1 D. MCDEVITT, IT P. FRANCOIS, 2P. E, VAUDAUX, 2 D. P. LEW 2 AND T. J. FOSTER 1.: "Adhesion properties of mutants of Staphylococcusaureus defective in fibronectin-binding proteins andstudies on the expression of fnb genes", MOLECULAR MICROBIOLOGY, vol. 17, no. 6, 1 January 1995 (1995-01-01), pages 1143 - 1152, XP055021884, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1111/j.1365-2958.1995.mmi_17061143.x/asset/j.1365-2958.1995.mmi_17061143.x.pdf?v=1&t=gzsgdde3&s=6df346b2dbdcbea9e2c139f563d52285213c07d8> [retrieved on 20120314] *
FRANCOIS ET AL: "Identification of plasma proteins adsorbed on hemodialysis tubing that promote Staphylococcus aureus adhesion", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, MOSBY, INC, US, vol. 135, no. 1, 1 January 2000 (2000-01-01), pages 32 - 42, XP005692144, ISSN: 0022-2143, DOI: 10.1016/S0022-2143(00)70018-7 *
PIERRE VAUDAUX ET AL: "Increased Expression of Clumping Factor and Fibronectin-Binding Proteins by hemB Mutants of Staphylococcus aureus Expressing Small Colony Variant Phenotypes", INFECTION AND IMMUNITY, 1 October 2002 (2002-10-01), pages 5428 - 5437, XP055021599, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC128368/pdf/1704.pdf> [retrieved on 20120312] *

Also Published As

Publication number Publication date
AU2016266066A1 (en) 2016-12-22
EP2616550B1 (en) 2016-02-10
EP2616550A2 (en) 2013-07-24
DK3067431T3 (en) 2019-10-14
EP3067431A1 (en) 2016-09-14
AU2011303467C1 (en) 2017-03-09
CY1122166T1 (en) 2020-11-25
CN107389932A (en) 2017-11-24
US20130164737A1 (en) 2013-06-27
EP3067431B1 (en) 2019-07-24
AU2016266066B2 (en) 2017-12-21
CN103108959B (en) 2017-06-09
PT3067431T (en) 2019-10-29
CN107389932B (en) 2019-11-22
US20210148940A1 (en) 2021-05-20
DK2616550T3 (en) 2016-05-23
PL3067431T3 (en) 2019-12-31
AU2011303467A1 (en) 2013-04-04
WO2012035508A2 (en) 2012-03-22
ES2751660T3 (en) 2020-04-01
CN103108959A (en) 2013-05-15
US20240280593A1 (en) 2024-08-22
HK1247280A1 (en) 2018-09-21
CA2811493A1 (en) 2012-03-22
JP5999776B2 (en) 2016-09-28
HUE045771T2 (en) 2020-01-28
WO2012035508A4 (en) 2012-07-19
US9689881B2 (en) 2017-06-27
JP2013538355A (en) 2013-10-10
AU2011303467B2 (en) 2016-09-15
SI3067431T1 (en) 2019-11-29
ES2571127T3 (en) 2016-05-24
US20170336424A1 (en) 2017-11-23
KR101948944B1 (en) 2019-02-15
PL2616550T3 (en) 2016-08-31
HRP20191785T1 (en) 2019-12-27
HUE028915T2 (en) 2017-01-30
KR20130107300A (en) 2013-10-01
CA2811493C (en) 2020-06-16
LT3067431T (en) 2019-11-11

Similar Documents

Publication Publication Date Title
WO2012035508A3 (en) Method for separating target molecules or particles from fibrinogen-containing samples including blood components
EP2477742B8 (en) Sample input device for inputting liquid samples (clot catcher)
WO2009121032A3 (en) Sample preparation devices and methods for processing analytes
WO2012162165A3 (en) Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof
EP2581156A4 (en) BINDER FOR SINGING LOW TEMPERATURE SINK, AND BONDING METHOD USING THE BINDER
WO2009125971A3 (en) Automatic refining apparatus, multi-well plate kit and method for extracting hexane from biological samples
EP2375244A4 (en) Blood coagulation system analyzer, and blood coagulation system analysis method and program
WO2012139047A3 (en) Identifying and enumerating early granulated cells (egcs)
CA3069089A1 (en) Compositions and methods for analyzing heterogeneous samples
EP2691170A4 (en) BLEACH-FREE ZEOLITIC ADSORBENTS, METHODS FOR PREPARING SAME, AND METHODS OF ADSORPTION SEPARATION USING THE SAME
EP2313771A4 (en) System and method for collecting plasma protein fractions from separated blood components
EP2130913A4 (en) Chip for sampling cell component, system for analyzing cell component and method of analyzing cell component using the same
BR112013030616A2 (en) test apparatus for collecting one or more wellbore fluid samples from a wellbore, and method for capturing a sample from a wellbore.
EA201000734A1 (en) METHOD AND APPARATUS FOR MONITORING THE SPATIAL FORMATION OF FIBRIC BUNCH
WO2012040603A3 (en) Use of diazolidinyl urea for anti-clumping of biological samples
WO2010080978A3 (en) Pre-depletion of leukocytes in whole blood samples prior to the capture of whole blood sample components
EP1890157A4 (en) Method for replacing liquid, method for extracting component by using it, composite container and automatic analyzer
WO2013144986A3 (en) Composition for processing histological, postmortem, cytological samples
WO2010028094A8 (en) Evaluating heparin preparations for pharmaceutical use
PL2352032T3 (en) Method for removing anti-endothelin-receptor antibodies from blood samples
WO2010031588A3 (en) Maldi matrices
WO2012080993A3 (en) Method and integrated system for improving data and service quality with respect to measurement and analysis of reservoir fluid samples
WO2008064232A3 (en) Fluidic antibody-containing devices and methods
WO2013093582A3 (en) Method and system for quantitative and qualitative analysis using mass spectrometry
WO2009089121A3 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180044211.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11788227

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13822209

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011788227

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013528815

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2811493

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011303467

Country of ref document: AU

Date of ref document: 20110915

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137009329

Country of ref document: KR

Kind code of ref document: A